Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol

Doo-Sun SIM; Myung-Ho JEONG; Hyo-Soo KIM; Hyeon-Cheol GWON; Ki-Bae SEUNG; Seung-Woon RHA; Shung-Chull CHAE; Chong-Jin KIM; Kwang-Soo CHA; Jong-Seon PARK; Jung-Han YOON; Jei-Keon CHAE; Seung-Jae JOO; Dong-Ju CHOI; Seung-Ho HUR; In-Whan SEONG; Myeong-Chan CHO; Doo-Il KIM; Seok-Kyu OH; Tae-Hoon AHN; Jin-Yong HWANG.
Journal of Lipid and Atherosclerosis ; : 208-220, 2019.
Artículo en Inglés | WPRIM | ID: wpr-765664

Documentos relacionados

  1. Effect of Statin Therapy on Cardiovascular Outcome in Stroke Patients with Low Baseline Low-Density Lipoprotein Cholesterol.
  2. More Than 50 Percent Reduction in LDL Cholesterol in Patients With Target LDL <70 mg/dL After a Stroke.
  3. How Will Our Practice Change After the CLEAR Outcomes Trial?
  4. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.
  5. Long-Lasting Control of LDL Cholesterol Induces a 40% Reduction in the Incidence of Cardiovascular Events: New Insights from a 7-Year Study.
  6. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
  7. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
  8. Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?
  9. Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program.
  10. A Translational Tool to Facilitate Use of Apolipoprotein B for Clinical Decision-Making.